Cetuximab activates ADCC through binding of its Fc region to NK cell receptor CD16/FcγRIII.95,99 The ability of cetuximab to stimulate ADCC can result in increased killing of EGFR+ CRC cells.100 Immune effects of cetuximab are observed regardless of tumor RAS/RAF mutational status in CRC.101 Cetuximab when combined with chemotherapy or immunotherapy has been shown to promote the recruitment of T cells, and NK cells to distal tumor sites.94,102 It has, therefore, been hypothesized that a combination of cetuximab and immunotherapy in CRC may elicit synergistic activity. This evidence concerns the gene EGFR and colorectal carcinoma.